solute carrier family 6 member 9Genealiases: GCENSG · GLYT1 · IS6
Q-omics provides the consensus-scored SLC6A9 profile across patient tissues and cancer cell-line models. SLC6A9 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, SLC6A9 is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, SLC6A9 RNA expression shows 18,637 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UCS, LIHC, and THYM as cancer lineages where SLC6A9 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SLC6A9 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SLC6A9 survival associations across molecular data types. SLC6A9 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (8) and mass-spec protein abundance (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SLC6A9 RNA expression–survival associations across cancer types. High SLC6A9 expression shows unfavorable associations in ACC, KICH, LGG and UCEC, but favorable associations in UCS and HNSC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for SLC6A9 RNA expression.
This table summarizes SLC6A9 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 1. The strongest signals are observed in LIHC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for SLC6A9. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SLC6A9 shows lower tumor expression in COAD, KIRP and READ and higher tumor expression in LIHC, BRCA and HNSC. The LIHC box plot shows higher SLC6A9 RNA expression in tumor versus normal tissue (log2 FC = +1.653, t-test p < 0.001).
This table shows molecular features associated with SLC6A9 in patient tissues and cancer cell lines. In patient samples, SLC6A9 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, SLC6A9 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in OESOPHAGUS and SKIN.
